Trial · NCT00972738
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline in Daytime Nasal Symptoms Score Over the 2-week Treatment Period | Montelukast 10 mg | -0.38 | 95% Confidence Interval -0.43 to -0.33 | Scores on a scale | |
| Mean Change From Baseline in Daytime Nasal Symptoms Score Over the 2-week Treatment Period | Loratadine 10 mg | -0.47 | 95% Confidence Interval -0.55 to -0.39 | Scores on a scale | |
| Mean Change From Baseline in Daytime Nasal Symptoms Score Over the 2-week Treatment Period | Placebo | -0.29 | 95% Confidence Interval -0.33 to -0.24 | Scores on a scale | |
| Mean Change From Baseline in Nighttime Symptoms Score Over the 2-week Treatment Period | Montelukast 10 mg | -0.28 | 95% Confidence Interval -0.32 to -0.24 | Scores on a scale | |
| Mean Change From Baseline in Nighttime Symptoms Score Over the 2-week Treatment Period | Loratadine 10 mg | -0.28 | 95% Confidence Interval -0.35 to -0.21 | Scores on a scale | |
| Mean Change From Baseline in Nighttime Symptoms Score Over the 2-week Treatment Period | Placebo | -0.20 | 95% Confidence Interval -0.25 to -0.16 | Scores on a scale | |
| Mean Change From Baseline in Daytime Eye Symptoms Score Over the 2-week Treatment Period | Montelukast 10 mg | -0.28 | 95% Confidence Interval -0.32 to -0.23 | Scores on a scale | |
| Mean Change From Baseline in Daytime Eye Symptoms Score Over the 2-week Treatment Period | Loratadine 10 mg | -0.40 | 95% Confidence Interval -0.47 to -0.32 | Scores on a scale | |
| Mean Change From Baseline in Daytime Eye Symptoms Score Over the 2-week Treatment Period | Placebo | -0.21 | 95% Confidence Interval -0.25 to -0.16 | Scores on a scale | |
| Patient's Global Evaluation of Allergic Rhinitis at the End of the 2-week Treatment Period | Montelukast 10 mg | 2.18 | 95% Confidence Interval 2.05 to 2.31 | Scores on a scale | |
| Patient's Global Evaluation of Allergic Rhinitis at the End of the 2-week Treatment Period | Loratadine 10 mg | 2.19 | 95% Confidence Interval 1.97 to 2.42 | Scores on a scale | |
| Patient's Global Evaluation of Allergic Rhinitis at the End of the 2-week Treatment Period | Placebo | 2.49 | 95% Confidence Interval 2.36 to 2.62 | Scores on a scale | |
| Physician's Global Evaluation of Allergic Rhinitis at the End of the 2-week Treatment Period | Montelukast 10 mg | 2.18 | 95% Confidence Interval 2.07 to 2.30 | Scores on a scale | |
| Physician's Global Evaluation of Allergic Rhinitis at the End of the 2-week Treatment Period | Loratadine 10 mg | 2.16 | 95% Confidence Interval 1.96 to 2.35 | Scores on a scale | |
| Physician's Global Evaluation of Allergic Rhinitis at the End of the 2-week Treatment Period | Placebo | 2.41 | 95% Confidence Interval 2.29 to 2.52 | Scores on a scale | |
| Mean Change From Baseline in Rhinoconjunctivitis Quality-of-Life Score After the 2-week Treatment Period | Montelukast 10 mg | -0.90 | 95% Confidence Interval -1.00 to -0.81 | Scores on a scale | |
| Mean Change From Baseline in Rhinoconjunctivitis Quality-of-Life Score After the 2-week Treatment Period | Loratadine 10 mg | -0.98 | 95% Confidence Interval -1.15 to -0.81 | Scores on a scale | |
| Mean Change From Baseline in Rhinoconjunctivitis Quality-of-Life Score After the 2-week Treatment Period | Placebo | -0.66 | 95% Confidence Interval -0.76 to -0.56 | Scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00972738/results